Key Takeaways
- Mazdutide is an oxyntomodulin analogue designed to activate GLP-1 and glucagon receptors.
- A randomized, double-blind Phase 2 study enrolled 179 adults at 24 US centres; participants had obesity or overweight and did not have type 2 diabetes.
- At week 32, least-squares mean bodyweight change ranged from −7.3% to −18.1% across the three mazdutide groups, compared with −0.9% for placebo.
- The registry reports further change at week 48, but the study had no active comparator and does not support claims that mazdutide is superior to another molecule.
- Gastrointestinal events were the most common; discontinuation due to adverse events was most frequent in the highest study group, at 20%.
- Mazdutide is not FDA-approved. WebberScience does not sell mazdutide.
The US Phase 2 mazdutide trial found model-adjusted, dose-dependent bodyweight reductions at 32 weeks in adults without type 2 diabetes. The strongest reported 32-week estimate was −18.1%, compared with −0.9% for placebo, but this was a company-funded Phase 2 study without an active comparator. It cannot establish real-world effectiveness, long-term safety, or superiority over Retatrutide or survodutide.
Research boundary: This article is scientific education, not medical advice. WebberScience materials are for research and laboratory use only, not for human or veterinary use. No dosing, route, administration, treatment, efficacy promise, safety guidance, or self-experimentation guidance is provided.
What Is Mazdutide?
An oxyntomodulin analogue and dual agonist
Mazdutide, also identified as LY3305677, is described in the peer-reviewed trial report as a glucagon and GLP-1 receptor dual agonist. Oxyntomodulin is an endogenous peptide that can signal through both receptor systems; mazdutide is an engineered analogue developed to study coordinated receptor activity.
A dual agonist is one molecule designed to activate two receptor targets. That label describes target design, not proven clinical superiority. The relative balance of activity, molecular structure, study population, trial duration, and statistical plan all matter.
Why GLP-1 and glucagon are studied together
GLP-1 receptor signaling is linked to glucose-dependent endocrine signaling, appetite-related pathways, and gastrointestinal physiology. Glucagon receptor signaling has important hepatic and energy-balance roles. Combining those targets creates a distinct research hypothesis, but a mechanistic rationale must remain separate from observed outcomes in a controlled trial.
How Was the US Phase 2 Trial Designed?
Population, allocation, and endpoints
The peer-reviewed report and ClinicalTrials.gov record NCT06124807 describe a randomized, double-blind, placebo-controlled Phase 2 trial at 24 US centres. The study randomized 179 adults aged 18–75. Eligible participants had a BMI of at least 30 kg/m², or a BMI from 27 to below 30 kg/m² with at least one weight-related comorbidity, and did not have type 2 diabetes.
The four randomized groups contained 48 placebo participants, 32 in the 3-to-6 mg group, 48 in the 10 mg group, and 51 in the 16 mg group. The primary endpoint was percentage change in bodyweight at week 32, evaluated with an efficacy, or hypothetical, estimand. Week 48 was a secondary time point.
| Study group | Randomized participants | Week-32 LS-mean change | Week-48 LS-mean change |
|---|---|---|---|
| Placebo | 48 | −0.85% | −0.047% |
| Mazdutide 3-to-6 mg group | 32 | −7.33% | −10.54% |
| Mazdutide 10 mg group | 48 | −15.6% | −19.2% |
| Mazdutide 16 mg group | 51 | −18.1% | −22.3% |
Values are model-adjusted least-squares means from the posted ClinicalTrials.gov results, not simple averages or individual predictions. Amount labels identify randomized study groups; they are not recommendations.
What an efficacy estimand asks
An estimand is the precise treatment-effect question a trial intends to answer. The efficacy or hypothetical estimand estimates the effect under defined assumptions about intercurrent events, such as stopping assigned study treatment. It differs from a treatment-regimen estimand that follows outcomes regardless of such events. Readers should not compare percentages across studies until they confirm that populations, time points, estimands, and missing-data methods align.
What least-squares mean means
A least-squares mean is a model-adjusted group estimate. The trial used a repeated-measures model with baseline, time, treatment, sex, and BMI-stratum terms. These adjusted values are appropriate for the prespecified analysis but are not equivalent to every participant’s observed change.
What Did the Trial Find at 32 Weeks?
A graded pattern across study groups
At week 32, the peer-reviewed abstract reports least-squares mean changes of −7.3%, −15.6%, and −18.1% for the three mazdutide groups, versus −0.9% for placebo. Estimated differences versus placebo ranged from −6.5 to −17.2 percentage points, with p<0.0001 for all three comparisons.
The graded pattern supports a dose-response observation within this protocol. It does not establish how people outside the trial would respond, whether the pattern persists over years, or whether a higher amount offers a favourable benefit-risk balance. Those are separate questions.
Why the placebo comparison matters
Randomization and placebo control help reduce confounding and expectation bias. Double masking further strengthens internal validity. However, placebo control does not answer whether mazdutide performs better or worse than another active investigational molecule.
What Happened at 48 Weeks?
The PubMed abstract states that additional bodyweight reductions were observed at week 48. The posted registry results provide the model-adjusted values: −10.54%, −19.2%, and −22.3% across the mazdutide groups, versus −0.047% for placebo.
Those values come from the same trial, but attrition matters. The registry participant-flow table reports that 128 of 179 randomized participants completed the overall study period. Completion counts were 29 of 48 for placebo, 28 of 32 for the 3-to-6 mg group, 37 of 48 for the 10 mg group, and 34 of 51 for the 16 mg group. The estimand and statistical handling of missing observations are therefore central to interpretation.
What Did the Safety Reporting Show?
Common events and discontinuation
The peer-reviewed abstract reports that the most common adverse events were gastrointestinal and mostly mild to moderate. Discontinuation of study treatment because of adverse events occurred most frequently in the 16 mg group, at 20%, and was primarily associated with gastrointestinal disorders.
“Mostly mild to moderate” does not support a universal safety conclusion. A Phase 2 trial of 179 randomized participants has limited power for uncommon events, long-latency outcomes, and population-specific risks. The study’s safety population also differed slightly from the randomized population because not every randomized participant received study treatment.
Mazdutide vs Retatrutide vs Survodutide
| Research molecule | Receptor design | Evidence milestone relevant here | Key comparison limit |
|---|---|---|---|
| Mazdutide | GLP-1 + glucagon dual agonist | US Phase 2 peer-reviewed report; NCT06124807 completed | No active comparator in the US trial |
| Retatrutide | GIP + GLP-1 + glucagon triple agonist | Phase 3 TRIUMPH-1 record, NCT05929066 | Different molecule, trials, populations, and analysis plans |
| Survodutide | GLP-1 + glucagon dual agonist | Phase 3 SYNCHRONIZE-1 findings reported in 2026 | Shared target labels do not make the molecules equivalent |
The scientifically defensible comparison is structural and developmental. Mazdutide and survodutide are both dual agonists, while Retatrutide adds GIP receptor activity. No direct randomized head-to-head study among these three was identified in the sources reviewed here. Ranking percentages from separate trials would ignore different durations, study populations, estimands, retention, and protocols.
For broader same-brand context, read WebberScience’s GLP-1/GIP/glucagon research comparison and metabolic research guide.
Regulatory Status: China Authorization, No FDA Approval
Innovent reported in June 2025 that China’s National Medical Products Administration approved mazdutide for chronic weight management in Chinese adults with overweight or obesity. That is a country-specific authorization. It does not create FDA approval or authorize use in Canada.
The FDA’s unapproved GLP-1 products page specifically names mazdutide among products illegally sold directly to consumers under false “research purposes” or “not for human consumption” labeling. FDA states that these products were accompanied by human-use instructions and were of unknown quality. A research label does not excuse consumer-directed drug marketing.
WebberScience does not sell mazdutide. This page reports published and registered evidence; it is not a product page or an availability claim.
Evidence Quality, Funding, and Replication
| Evidence feature | What strengthens confidence | What limits confidence |
|---|---|---|
| Design | Randomized, double-blind, placebo-controlled, multicentre | No active comparator; Phase 2 scale |
| Population | 179 participants at US centres with defined eligibility | Adults without type 2 diabetes; findings do not automatically transfer to other populations |
| Analysis | Prespecified endpoint and model-adjusted estimates | Hypothetical estimand and attrition require careful interpretation |
| Funding and authorship | Peer-reviewed report and public registry results | Funded by Eli Lilly; nine listed authors were Lilly employees and stockholders |
| Replication | Results are consistent across published abstract and registry record | Independent replication of this exact US protocol was not identified |
Industry funding does not invalidate a trial, but it is part of evidence appraisal. The PubMed conflict statement identifies nine authors as Eli Lilly employees and stockholders; other investigators disclosed research support or consulting relationships. Confidence would increase with independent analyses, longer follow-up, and direct comparisons designed around the same population and estimand.
What This Trial Does Not Establish
- It does not establish that mazdutide is FDA-approved, available through WebberScience, or appropriate for personal use.
- It does not prove superiority to Retatrutide, survodutide, or another molecule because there was no active comparator.
- It does not establish long-term outcomes beyond the study period.
- It does not define outcomes for people with type 2 diabetes or populations excluded by the protocol.
- It does not turn a group-level least-squares mean into an individual prediction.
- It does not resolve rare-event safety at Phase 2 scale.
Key Terms and Definitions
- Oxyntomodulin analogue
- An engineered molecule based on a peptide that can signal through GLP-1 and glucagon receptor systems.
- Dual agonist
- One molecule designed to activate two receptor targets.
- GLP-1 receptor
- A receptor involved in glucose-dependent endocrine signaling, gastrointestinal physiology, and appetite-related pathways.
- Glucagon receptor
- A receptor with important roles in hepatic metabolism and energy balance.
- Efficacy estimand
- A prespecified treatment-effect question using hypothetical assumptions for defined intercurrent events.
- Least-squares mean
- A model-adjusted group estimate produced by the trial’s statistical analysis.
- Active comparator
- Another active study intervention used as the control instead of, or alongside, placebo.
Frequently Asked Questions About the Mazdutide US Phase 2 Trial
What is mazdutide?
Mazdutide, also called LY3305677, is an oxyntomodulin analogue designed to activate the GLP-1 and glucagon receptors. It is a dual agonist, not a triple agonist.
What did the US Phase 2 mazdutide trial find?
At week 32, least-squares mean bodyweight changes were −7.3%, −15.6%, and −18.1% across the three mazdutide groups, compared with −0.9% for placebo. These are trial estimates, not predictions for individuals.
Who was enrolled in the trial?
The study randomized 179 US adults aged 18–75 with obesity, or overweight plus at least one related comorbidity, who did not have type 2 diabetes. The mean age was 47.7 years and 66% were female.
What happened at 48 weeks?
The ClinicalTrials.gov results record reports least-squares mean changes of −10.54%, −19.2%, and −22.3% across the mazdutide groups, versus −0.047% for placebo. Cross-trial comparisons remain unreliable.
What is an efficacy estimand?
An estimand defines the treatment effect a trial is trying to estimate. The efficacy, or hypothetical, estimand asks what the average effect would look like under specified assumptions about events such as treatment discontinuation.
What does least-squares mean mean?
A least-squares mean is a model-adjusted group estimate rather than a simple raw average. It reflects the trial’s prespecified statistical model and should be interpreted with its standard error and comparator.
What adverse events were reported?
The PubMed abstract says the most common events were gastrointestinal and mostly mild to moderate. Study-treatment discontinuation due to adverse events was most frequent in the highest group, at 20%.
Is mazdutide FDA-approved?
No. FDA identifies mazdutide among unapproved GLP-1-related products that have been illegally sold directly to consumers under false research-use labeling.
Is mazdutide approved anywhere?
Innovent reported that China’s National Medical Products Administration approved mazdutide for chronic weight management in Chinese adults in June 2025. That authorization does not apply in the United States or Canada.
How is mazdutide different from Retatrutide?
Mazdutide is designed around GLP-1 and glucagon receptor activity. Retatrutide is designed around GIP, GLP-1, and glucagon receptors. There is no direct head-to-head trial between them in the sources reviewed here.
How does mazdutide compare with survodutide?
Both are GLP-1/glucagon dual agonists, but they are different molecules studied in different programs. Separate trials cannot establish which is better without a direct randomized comparison.
Does WebberScience sell mazdutide?
No. WebberScience does not list mazdutide. Its related catalog materials are GLP-3 (Ret) research products, which are chemically and evidentially distinct and are for laboratory research only.
Primary and Authoritative Sources
- Hsia SH, et al. “Efficacy and safety of mazdutide in adults with obesity or overweight: a US-based, multicentre, phase 2, randomised, placebo-controlled clinical trial.” The Lancet Diabetes & Endocrinology. 2026. PMID 42628555; DOI 10.1016/S2213-8587(26)00160-9.
- ClinicalTrials.gov NCT06124807. Protocol, statistical plan, participant flow, outcomes, and posted results.
- US Food and Drug Administration. “FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss.”
- Innovent announcement of China NMPA authorization for chronic weight management. June 2025; company source.
- ClinicalTrials.gov NCT05929066, the Phase 3 TRIUMPH-1 Retatrutide record. Used only for receptor-design and development-status context.
- Boehringer Ingelheim 2026 SYNCHRONIZE-1 results. Company source; used only for development-status context.
Continue Incretin Research at WebberScience
WebberScience does not sell mazdutide. Qualified researchers can review the distinct GLP-3 (Ret) 10mg research listing or GLP-3 (Ret) 5mg research listing. The labeled vial strength is product quantity only—not a dose, study amount, protocol, route, or evidence of equivalence to mazdutide.
Additional context is available in the WebberScience Research Guides.
Research disclaimer: For research and laboratory use only. Not intended for human or veterinary use. This article does not constitute medical advice. WebberScience provides no dosing, route, administration, treatment, efficacy, safety, or self-experimentation guidance.